Incorporating monoclonal antibodies in blood and marrow transplantation

Seminars in Oncology

Volumn 30, Issue 4, 2003, Pages 520-530

  Malek, Sami N ^b   Flinn, Ian W ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CARMUSTINE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; MELPHALAN; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131;

ANOREXIA; B CELL LYMPHOMA; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; LEUKOENCEPHALOPATHY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; REVIEW; VARICELLA ZOSTER VIRUS;

EID: 0042737435     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00238-0     Document Type: Article

References (39)

1. Leonard BM, Hetu F, Busque L, et al: Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood 91:331-339, 1998
2. Gribben JG, Freedman A, Woo SD, et al: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275-3280, 1991
3. Ladetto M, Corradini P, Vallet S, et al: High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: A multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 100:1559-1565, 2002
4. Gribben JG, Freedman AS, Neuberg D, et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325:1525-1533, 1991
5. Freedman AS, Neuberg D, Mauch P, et al: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333, 1999
6. Apostolidis J, Gupta RK, Grenzelias D, et al: High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 18:527-536, 2000
7. Horning SJ, Negrin RS, Hoppe RT, et al: High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial. Blood 97:404-409, 2001
8. Williams CD, Goldstone AH, Pearce RM, et al: Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 14:2454-2464, 1996
9. Schouten HC, Qian W, Sydes MR, et al: High dose therapy improves progression free survival and survival in relapsed follicular non-Hodgkin's lymphoma; results from the randomized European CUP trial, in Dicke KA, Keating A (eds): The Eleventh International ABMT Symposium on Stem Cell and Targeted Therapy. Arlington, TX, Carden Jennings, 2002
10. Vriesendorp HM, Herpst JM, Germack MA, et al: Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J Clin Oncol 9:918-928, 1991
11. Bierman PJ, Vose JM, Leichner PK, et al: Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease. J Clin Oncol 11:698-703, 1993
12. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993
13. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995
14. Press OW, Eary JF, Gooley T, et al: A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934-2942, 2000
15. Vose JM, Bierman PJ, Lynch JC, et al: Radioimmunotherapy with Bexxar combined with high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for refractory non-Hodgkin's lymphoma: Synergistic results with no added toxicity. ASCO Educational Book. San Francisco, CA, American Society of Clinical Oncology, 2001, p 6a
16. Behr TH, Griesinger F, Riggert J, et al: High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin's lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Cancer 94:1363-1372, 2002 (suppl)
17. Gopal AK, Rajendran JG, Petersdorf SH, et al: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99:3158-3162, 2002
18. Winter JN, Inwards D, Erwin W, et al: Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenotir cell (PBPC) transplant in non-Hodgkin's lymphoma: early outcome results. Blood 100:411a, 2002 (suppl 1, abstr)
19. Nademanee A, Molina A, Forman SJ: A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL). Blood 100:182a, 2002 (suppl 1, abstr)
20. Demidem A, Lam A, Alas S, et al: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Chemother Radiopharmaceut 12:177-186, 1997
21. Alas S, Emmanouilides C, Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7:709-723, 2001
22. Magni M, Di Nicola M, Devizzi L, et al: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood 96:864-869, 2000
23. Gianni AM, Cortelazzo S, Magni M, et al: Rituximab: Enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant 29:S10-13, 2002 (suppl)
24. Flinn IW, O'Donnell PV, Goodrich A, et al: Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 6:628-632, 2000
25. Flinn IW, Diehl L, Garrett E, et al: In vivo purging and post transplant immunotherapy with rituximab produces durable remissions in patients with low grade and mantle cell lymphoma. Biol Blood Marrow Transplanat 9:70, 2003
26. Voso MT, Pantel G, Weis M, et al: In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/ mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 109:729-735, 2000
27. Lazzarino M, Arcaini L, Bernasconi P, et al: A sequence of immuno-chemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 116:229-35, 2002
28. Buckstein R, Imrie K, Spaner D, et al: Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 26:115-122, 1999
29. Horwitz S, Negrin RS, Stockert-Goidstein K, et al: Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma. Blood 98:3578a, 2001 (suppl 1, abstr)
30. Brugger W: Improving outcomes in transplantation. Semin Oncol 29:23-26, 2002
31. van der Kolk LE, Baars JW, Prins MH, et al: Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100:2257-2259, 2002
32. Goldberg SL, Pecora AL, Atter RS, et al: Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99:1486-1488, 2002
33. Flohr T, Hess G, Kolbe K, et al: Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 29:769-775, 2002
34. Tarella C, Ladetto M, Magni M, et al: Rituximab-supplemented high-dose chemotherapy with autografting in high-risk B-diffuse large cell lymphoma: A multicenter, prospective study of GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Blood 100:647a, 2002 (suppl 1, abstr)
35. Ladetto M, Zallio F, Vallet S, et al: Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 15:1941-1949, 2001
36. Papadaki T, Stamatopoulos K, Tsompanakou A, et al: A spectrum of immunohematological sequellae developing in rituximab-treated lymphoma patients in a setting of T-large granular lymphocyte (T-LGL) mediated immune myelopathy. Blood 100:353a, 2002 (suppl 1, abstr)
37. Blum KA, Hidalgo J, Khoury H, et al: Delayed neutrophil and platelet engraftment following autologous transplantation in non-Hodgkins lymphoma patients previously treated with rituximab. Blood 100:643a, 2002 (suppl 1, abstr)
38. Press OW, Corcoran M, Subbiah K, et al: A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 98:2535-2543, 2001
39. Pagel JM, Hedin N, Subbiah K, et al: A comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 101:2340-2348, 2002